Physician
Hematology
Dr. Naoko N. Takebe, MD
Naoko N. Takebe, MD is an expert in the field of Hematology. Naoko Takebe is a published MD. She published 47 publications, including: 'Purine salvage rescue by xanthine-guanine phosphoribosyltransferase (XGPRT) potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reduct...'
Publications
- Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
- Perspectives on research activity in the USA on Cancer Precision Medicine.
- Biomarkers: Exceptional responders-discovering predictive biomarkers.
- Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT) Activity by Small Molecule GMX1778 Regulates Reactive Oxygen Species (ROS)-mediated Cytotoxicity in a p53-...
- Psychosocial factors are independent risk factors for the development of Type 2 diabetes in Japanese workers with impaired fasting glucose and/or impaired glucose tole...
- Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
- Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.
- Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients.
- Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin''s lymphoma.
- Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study.
- Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma.
- Gene therapy for endometrial carcinoma with the herpes simplex thymidine kinase gene.
- Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated d...
- High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity.
- Co-expression of the herpes simplex virus thymidine kinase gene potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene.
- Protection of bone marrow cells from toxicity of chemotherapeutic agents targeted toward thymidylate synthase by transfer of mutant forms of human thymidylate synthase...
- Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enr...
- Comparison of methotrexate resistance conferred by a mutated dihydrofolate reductase (DHFR) cDNA in two different retroviral vectors.
- Purine salvage rescue by xanthine-guanine phosphoribosyltransferase (XGPRT) potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reduct...
- Targeting the Hedgehog pathway in cancer.
- Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition.
- KIT as a therapeutic target in metastatic melanoma.
- A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
- Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
- Principles and current strategies for targeting autophagy for cancer treatment.
- Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways.
- Molecular conversations and the development of the hair follicle and basal cell carcinoma.
- Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.
- Controversies in cancer stem cells: targeting embryonic signaling pathways.
- Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan.
- A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
- NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide.
- Preliminary findings on the use of pulsatile machine reperfusion of a placenta to improve the cord blood collection yield including primitive hematopoietic stem cell f...
- RCAS/SCL-TVA animal model allows targeted delivery of polyoma middle T oncogene to vascular endothelial progenitors in vivo and results in hemangioma development.
- Human brain endothelial cells (HUBEC) promote SCID repopulating cell expansion through direct contact.
- Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
- IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells.
- Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
- Multiple myeloma presenting initially as a solitary pleural effusion later complicated by malignant plasmacytic ascites.
- Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.
- Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene.
- Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-flu...
- Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome.
- Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reducta...
- Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.
- Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ...
Schools
Hirosaki University School of Medicine
Calif Pacific Med Center
US Naval Hospital
Keio University
Meml Sloan Kettering Cancer Center
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Memorial Sloan-Kettering Cancer Center -
California Pacific Medical Center - Pacific Campus
Helpful Reviews
Similar Doctors
|
Dr. Helen X. Chen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Farah Z. Zia, MD |
|
|
Dr. Nicholas J. Farrell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul A. Bannen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert L. Justice III, MD |
|
|
Dr. Chaohong Fan, MD |
|
|
Dr. Richard J. Benjamin, MD |
|
|
Dr. Barnett S. Kramer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Neil E. Caporaso, MD |
|
|
Dr. Joseph C. Fratantoni, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angela Manns, MD |
|
|
Dr. Dongmei Wang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chitra D. Rajagopal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph M. Haggerty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John M. Wallmark, MD
This Doctor is OpenDoctor Recommended.
|